EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Albiglutide; Alogliptin; Dipeptidyl peptidase 4 inhibitors; Dulaglutide; Exenatide; Glucagon-like peptide-1 receptor agonists; Linagliptin; Liraglutide; Lixisenatide; Saxagliptin; Semaglutide; Sitagliptin
Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
Focus Adverse reactions; Therapeutic Use
Acronyms EMPRISE; EMPRISE United States
Sponsors Boehringer Ingelheim

13 Jul 2023 Planned End Date changed from 30 Jun 2022 to 31 Dec 2024.
13 Jul 2023 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2024.
28 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com